Previous close | 101.40 |
Open | 100.20 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 100.20 - 101.60 |
52-week range | 100.20 - 101.60 |
Volume | |
Avg. volume | 0 |
Market cap | 260.608B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 21.04 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RAHWAY, N.J., July 01, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation ("Orion") today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
RAHWAY, N.J., July 01, 2024--Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
RAHWAY, N.J., June 28, 2024--Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)